Literature DB >> 24500247

[Radiological diagnostics in CUP syndrome].

P M Kazmierczak1, K Nikolaou, A Rominger, A Graser, M F Reiser, C C Cyran.   

Abstract

CLINICAL/METHODICAL ISSUE: Imaging plays an essential role in the therapeutic management of cancer of unknown primary (CUP) patients for localizing the primary tumor, for the identification of tumor entities for which a dedicated therapy regimen is available and for the characterization of clinicopathological subentities that direct the subsequent diagnostic and therapeutic strategy. STANDARD RADIOLOGICAL
METHODS: Modalities include conventional x-ray, computed tomography (CT), magnetic resonance imaging (MRI) and ultrasound as well as positron emission tomography (PET)-CT and MRI-PET. PERFORMANCE: In whole body imaging CT has a high sensitivity for tumor entities which frequently present as a metastasized cancer illness. According to the current literature CT is diagnostic in 86% of patients with pancreatic carcinoma, in 36% of patients with colon carcinoma and in 74% of patients with lung carcinoma. Additionally a meta-analysis showed that for patients with squamous cell carcinoma and cervical lymph node metastases a positive diagnosis was possible in 22% of the cases using CT, in 36% using MRI and in 28-57% using 18F-fluorodeoxyglucose PET-CT ((18)F-FDG PET-CT). In addition, MRI plays an important role in the localization of primary occult tumors (e.g. breast and prostate) because of its high soft tissue contrast and options for functional imaging. ACHIEVEMENTS: At the beginning of the diagnostic algorithm stands the search for a possible primary tumor and CT of the neck, thorax and abdomen is most frequently used for whole body staging. Subsequent organ-specific imaging examinations follow, e.g. mammography in women with axillary lymphadenopathy. For histological and immunohistochemical characterization of tumor tissue, imaging is also applied to identify the most accessible and representative tumor manifestation for biopsy. Tumor biopsy may be guided by CT, MRI or ultrasound and MRI also plays a central role in the localization of primary occult tumors because of superior soft tissue contrast and options for functional imaging (perfusion, diffusion), e.g. investigation of breast carcinoma or prostate carcinoma. PRACTICAL RECOMMENDATIONS: Whole body staging stands at the beginning of the diagnostic algorithm in CUP syndrome to localize a potential primary tumor. Clinically, contrast-enhanced CT of the neck, thorax and abdomen is frequently applied; however, many studies have demonstrated augmented sensitivity of (18)F-FDG PET-CT for the detection of primary tumors and metastatic tumor manifestations.

Entities:  

Mesh:

Year:  2014        PMID: 24500247     DOI: 10.1007/s00117-013-2547-9

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  40 in total

1.  Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992.

Authors:  A J van de Wouw; M L G Janssen-Heijnen; J W W Coebergh; H F P Hillen
Journal:  Eur J Cancer       Date:  2002-02       Impact factor: 9.162

2.  Clinical utility and prospective comparison of ultrasonography and computed tomography imaging in staging of neck metastases in head and neck squamous cell cancer in an Indian setup.

Authors:  Mohammad Ashraf; Jaydip Biswas; Jayesh Jha; Sandeep Nayak; Vikas Singh; Suparna Majumdar; Anup Bhowmick; Aniruddha Dam
Journal:  Int J Clin Oncol       Date:  2011-06-16       Impact factor: 3.402

Review 3.  Cancer of unknown primary site.

Authors:  Nicholas Pavlidis; George Pentheroudakis
Journal:  Lancet       Date:  2012-03-12       Impact factor: 79.321

4.  A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network.

Authors:  P H S Shaw; R Adams; C Jordan; T D L Crosby
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-02       Impact factor: 4.126

5.  Is mammography of value in women with disseminated cancer of unknown origin?

Authors:  K J Stevens; S L Smith; H Denley; S E Pinder; A J Evans; S Y Chan
Journal:  Clin Oncol (R Coll Radiol)       Date:  1999       Impact factor: 4.126

Review 6.  [Ultrasound in oncology: screening and staging].

Authors:  S Delorme
Journal:  Internist (Berl)       Date:  2012-03       Impact factor: 0.743

7.  [Immunohistochemical diagnosis in cancer metastasis of unknown primary tumor].

Authors:  O Kaufmann; E Fietze; M Dietel
Journal:  Pathologe       Date:  2002-05       Impact factor: 1.011

Review 8.  Carcinoma of unknown primary (CUP).

Authors:  Nicholas Pavlidis; Karim Fizazi
Journal:  Crit Rev Oncol Hematol       Date:  2008-11-01       Impact factor: 6.312

Review 9.  Diagnostic and therapeutic management of cancer of an unknown primary.

Authors:  N Pavlidis; E Briasoulis; J Hainsworth; F A Greco
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

10.  Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.

Authors:  J L Abbruzzese; M C Abbruzzese; R Lenzi; K R Hess; M N Raber
Journal:  J Clin Oncol       Date:  1995-08       Impact factor: 44.544

View more
  1 in total

1.  68Ga-TRAP-(RGD)3 Hybrid Imaging for the In Vivo Monitoring of αvß3-Integrin Expression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental Breast Cancer.

Authors:  Philipp M Kazmierczak; Andrei Todica; Franz-Josef Gildehaus; Heidrun Hirner-Eppeneder; Matthias Brendel; Ralf S Eschbach; Magdalena Hellmann; Konstantin Nikolaou; Maximilian F Reiser; Hans-Jürgen Wester; Saskia Kropf; Axel Rominger; Clemens C Cyran
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.